Sugi Predict

Sugi Predict / Compounds / SCHEMBL146169

SCHEMBL146169

SCHEMBL146169

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4ccccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CNCC1CC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 9/20 0.73
▸ FGFR1 P11362 9/20 0.73
▸ PDGFRB P09619 8/20 0.73
▸ MET P08581 7/20 0.73
▸ SRC P12931 4/20 0.73
▸ EGFR P00533 3/20 0.73
▸ ALK Q9UM73 3/20 0.73
▸ CDK2 P24941 2/20 0.73
▸ PTK2B Q14289 2/20 0.73
▸ MEN1 O00255 2/20 0.73
▸ KMT2A Q03164 2/20 0.73
▸ TDP1 Q9NUW8 2/20 0.73
▸ ABL1 P00519 2/20 0.73
▸ RET P07949 2/20 0.73
▸ FLT3 P36888 2/20 0.73
▸ LCK P06239 2/20 0.73
▸ YES1 P07947 2/20 0.73
▸ KIT P10721 2/20 0.73
▸ NEK2 P51955 2/20 0.73
▸ PLK4 O00444 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL147371 0.94 KDR (0.70) KDRFGFR1PDGFRBMETSRC
SCHEMBL144320 0.93 KDR (0.83) KDRFGFR1PDGFRBMETSRC
SCHEMBL143330 0.93 KDR (0.83) KDRFGFR1PDGFRBMETSRC
SCHEMBL142850 0.93 KDR (0.66) KDRFGFR1PDGFRBMETSRC
SCHEMBL148118 0.92 KDR (0.87) KDRFGFR1PDGFRBMETSRC
SCHEMBL142996 0.91 KDR (0.67) KDRFGFR1PDGFRBMETSRC
SCHEMBL144525 0.88 KDR (0.71) KDRFGFR1PDGFRBMETSRC
SCHEMBL145766 0.87 KDR (0.81) KDRFGFR1PDGFRBMETSRC
SCHEMBL141038 0.87 KDR (0.81) KDRFGFR1PDGFRBMETSRC
SCHEMBL7126847 0.86 KDR (0.65) KDRFGFR1PDGFRBMETSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 — — US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 — — US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 — — US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 — — US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 — — US disclosed
WO-2005065686-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) 2005-07-21 — — WO disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 KDR 1077/4885FGFR1 5/4885PDGFRB 467/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 KDR 1077/4885FGFR1 5/4885PDGFRB 467/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 KDR 398/4885FGFR1 637/4885PDGFRB 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.